Phase 1 Study of IMC-002, a Next-Generation Anti-CD47 Antibody, in Advanced Solid Tumors
IMC-002 demonstrated favorable safety/tolerability at doses of 5-30 mg/kg every 2 weeks. RP2D was defined as 20 mg/kg every 3 weeks. Preliminary anti-tumor activity was observed, with a CBR of 33%.
Authors
- Heung Tae Kim
- Jung Yong Hong (ORCID: https://orcid.org/0000-0003-1363-9332)
- Ho Yeong Lim (ORCID: https://orcid.org/0000-0001-9325-2300)
- Hwi‐yeol Yun (ORCID: https://orcid.org/0000-0001-8793-2449)
- Joon Oh Park (ORCID: https://orcid.org/0000-0001-6502-2612)
- Woochan Hwang
- Jin Seok Ahn (ORCID: https://orcid.org/0000-0002-2880-6730)
- Suyeon Kim (ORCID: https://orcid.org/0000-0002-3691-7692)
- Sung Young Lee (ORCID: https://orcid.org/0000-0002-4155-4195)
- Sung Ho Kim
- Chan-Young Ock
Institutions
- Chungnam National University (KR)
- Samsung Medical Center (KR)
- Abeona Therapeutics (United States) (US)
- Sungkyunkwan University (KR)
Publication Details
- Journal
- Cancer Research and Treatment
- Published
- 2025-11-04
- DOI
- https://doi.org/10.4143/crt.2025.820
- Primary Topic
- Phagocytosis and Immune Regulation
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Eli Lilly and Company
- AstraZeneca
- Celgene
- Moderna
- AstraZeneca Korea
- Servier
- LG Chem
- Daiichi Sankyo Europe